Understanding CGRP and cardiovascular risk

Eloísa Rubio-Beltrán; Antoinette Maassen van den Brink

doi:10.1007/164_2019_204

Understanding CGRP and cardiovascular risk

Eloísa Rubio-Beltrán, Antoinette Maassen van den Brink^*

^*Corresponding author for this work

Wolfson SPaRC

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

15 Citations (Scopus)

Abstract

Increasing knowledge about the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has led to the development of antibodies against this peptide or its receptor. However, CGRP is widely expressed throughout the body, participating not only in pathophysiological conditions but also in several physiological processes and homeostatic responses during pathophysiological events. Therefore, in this chapter, the risks of long-term blockade of the CGRP pathway will be discussed, with focus on the cardiovascular system, as this peptide has been described to have a protective role during ischemic events, and migraine patients present a higher risk of stroke and myocardial infarction.

Original language	English
Title of host publication	Handbook of Experimental Pharmacology
Publisher	Springer New York LLC
Pages	131-140
Number of pages	10
DOIs	https://doi.org/10.1007/164_2019_204
Publication status	Published - 2019

Publication series

Name	Handbook of Experimental Pharmacology
Volume	255
ISSN (Print)	0171-2004
ISSN (Electronic)	1865-0325

Keywords

Cardiovascular safety
CGRP
CGRP (receptor) antibodies
Migraine
Myocardial infarction
Stroke

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/164_2019_204

Cite this

@inbook{43cad6f69bde4ee7916ebb15f463bd1a,

title = "Understanding CGRP and cardiovascular risk",

abstract = "Increasing knowledge about the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has led to the development of antibodies against this peptide or its receptor. However, CGRP is widely expressed throughout the body, participating not only in pathophysiological conditions but also in several physiological processes and homeostatic responses during pathophysiological events. Therefore, in this chapter, the risks of long-term blockade of the CGRP pathway will be discussed, with focus on the cardiovascular system, as this peptide has been described to have a protective role during ischemic events, and migraine patients present a higher risk of stroke and myocardial infarction.",

keywords = "Cardiovascular safety, CGRP, CGRP (receptor) antibodies, Migraine, Myocardial infarction, Stroke",

author = "Elo{\'i}sa Rubio-Beltr{\'a}n and {van den Brink}, {Antoinette Maassen}",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Nature Switzerland AG.",

year = "2019",

doi = "10.1007/164_2019_204",

language = "English",

series = "Handbook of Experimental Pharmacology",

publisher = "Springer New York LLC",

pages = "131--140",

booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - Understanding CGRP and cardiovascular risk

AU - Rubio-Beltrán, Eloísa

AU - van den Brink, Antoinette Maassen

PY - 2019

Y1 - 2019

N2 - Increasing knowledge about the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has led to the development of antibodies against this peptide or its receptor. However, CGRP is widely expressed throughout the body, participating not only in pathophysiological conditions but also in several physiological processes and homeostatic responses during pathophysiological events. Therefore, in this chapter, the risks of long-term blockade of the CGRP pathway will be discussed, with focus on the cardiovascular system, as this peptide has been described to have a protective role during ischemic events, and migraine patients present a higher risk of stroke and myocardial infarction.

AB - Increasing knowledge about the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has led to the development of antibodies against this peptide or its receptor. However, CGRP is widely expressed throughout the body, participating not only in pathophysiological conditions but also in several physiological processes and homeostatic responses during pathophysiological events. Therefore, in this chapter, the risks of long-term blockade of the CGRP pathway will be discussed, with focus on the cardiovascular system, as this peptide has been described to have a protective role during ischemic events, and migraine patients present a higher risk of stroke and myocardial infarction.

KW - Cardiovascular safety

KW - CGRP

KW - CGRP (receptor) antibodies

KW - Migraine

KW - Myocardial infarction

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85071782542&partnerID=8YFLogxK

U2 - 10.1007/164_2019_204

DO - 10.1007/164_2019_204

M3 - Chapter

C2 - 30879200

AN - SCOPUS:85071782542

T3 - Handbook of Experimental Pharmacology

SP - 131

EP - 140

BT - Handbook of Experimental Pharmacology

PB - Springer New York LLC

ER -

Understanding CGRP and cardiovascular risk

Abstract

Publication series

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this